By James Carstensen | May 12, 2021 | 7:37pm EDT
Chinese President Xi Jinping, French President Emmanuel Macron, and German Chancellor Angela Merkel in Paris in 2019. (Photo by Chesnot/Getty Images)
Berlin (CNSNews.com) – A little-noticed clause in a troubled China-European Union investment agreement, requiring senior executives of foreign non-governmental organizations (NGOs) to be Chinese, is causing a stir in Germany.
Lawmakers and non-profits have expressed concern over the clause, inserted into an annex of the Comprehensive Agreement on Investment (CAI). It states that “the senior executives of non-profit organizations which have been approved to be established within the territory of China shall be Chinese citizens.”
Updated:
April 29, 2021 10:22 IST
Her investigations in zebra fish have helped elucidate genes and other cellular substances involved in human development.
Share Article
AAA
Her investigations in zebra fish have helped elucidate genes and other cellular substances involved in human development.
Christiane Nusslein-Volhard is a German geneticist, who was the co-recipient of the 1995 Nobel Prize in Physiology or Medicine for her research on the mechanisms of early embryonic development. Christiane Nusslein-Volhard was born in Heyrothsberge, Germany, in 1942. Christiane studied biology at Goethe University in Frankfurt and biochemistry at Eberhard-Karl University, Tubingen, before undertaking graduate studies at the Max Planck Institute.
Upon completing her PhD in genetics in 1973, Chritiane joined the University of Basel. There she undertook gene study on Drosophila, or fruit flies, an important model organism in genetics. In 1978, she joined the European Molecular Biology L
Doris Reisinger, an abuse survivor and former nun, speaks at a news conference in Rome Feb. 19, 2019. (CNS/Paul Haring)
Doris Reisinger is one of four speakers in a webinar series on spiritual abuse on April 28 and May 18 by the Union of the European Conferences of Major Superiors. Reisinger was the recipient of the 2020 Christine Schenk Award for Outstanding Young Catholic Leadership by FutureChurch for her testimony and writings about spiritual and sexual abuse of women, particularly women religious, by clergy.
She has also been critical of the structures and culture that keep most women in a position of unquestioning obedience to a superior, as FutureChurch notes. That culture, she said in her address (under her former name Doris Wagner) at the Voices of Faith event Overcoming Silence - Women s Voices in the Abuse Crisis in November 2018, is what prevented her from speaking out for two years about her own case of being raped by a priest. She had entered rel
In conversations with other women, we ve discussed how Mary the mother of Jesus is often used as a model for us, but in what we consider a caricature as only mother, pure and chaste, asexual, dedicated to serving others and submissive, and leaving out her need for support, her independence, courage, questioning, strength and authority. Image: a statue of Mary at Our Lady of Fatima in Brazil (Unsplash/Mateus Campos Felipe)
There has been much written recently about rising incidents of abuse and violence against women, including an important meeting of the U.N. Commission on Women. Through conversations about this, I also learned of another kind of abuse: spiritual/religious abuse. Although the term was new to me, the stories from women who have experienced it are not new. It was and is experienced in the context of obedience to church leaders, church teachings and projected images of women that tend to shame them.
PerkinElmer, Inc.: PerkinElmer Supports PROXIDRUGS Consortium Aimed at Advancing Targeted Protein Degradation/PROTAC Drugs
Leading academic and industry cluster to help address 80% of disease-relevant human proteins currently undruggable PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras). PROTACs are a new class of drugs that take advantage of the body s own cell protein recycling system to fight disease by tapping into the 80% of disease-relevant proteins that are currently untargeted by today s available therapeutics. Led by Goethe University in Frankfurt, Germany, the Consortium includes researchers from the Technical University of Darmstadt, the Fraunhofer Institute for Translational Medicine and Pharmacology